Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: A community-based, randomised controlled trial

The Lancet Infectious Diseases

Volumn 12, Issue 2, 2012, Pages 128-135

  Estívariz, Concepción F ^a   Jafari, Hamid ^b   Sutter, Roland W ^c   John, T Jacob ^d   Jain, Vibhor ^e   Agarwal, Ashutosh ^e   Verma, Harish ^b   Pallansch, Mark A ^a   Singh, Ajit P ^f   Guirguis, Sherine ^g   Awale, Jitendra ^h   Burton, Anthony ^c   Bahl, Sunil ^b   Chatterjee, Arani ^f   Aylward, R Bruce ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b National Polio Surveillance Project   (India)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d CHRISTIAN MEDICAL COLLEGE   (India)

^e National Polio Surveillance Project   (India)

^f Panacea Biotec Ltd   (India)

^g UNICEF   (United States)

^h Child Survival Collaborations and Resource Group   (India)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE; TRIPLE VACCINE; TYPE 1 MONOVALENT POLIOVIRUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIARRHEA; DRUG POTENCY; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNOGENICITY; INDIA; INFANT; MALE; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROPREVALENCE; SINGLE DRUG DOSE; SKIN REDNESS; SWELLING; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTIBODIES, VIRAL; FEMALE; HUMANS; INDIA; INFANT; MALE; NEUTRALIZATION TESTS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; VACCINATION;

EID: 84856210551     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70190-6     Document Type: Article

References (30)

1. Progress toward interruption of wild poliovirus transmission-worldwide, 2008. MMWR Morb Mortal Wkly Rep 2009, 58:308-312. Centers for Disease Control and Prevention (CDC).
2. Progress toward poliomyelitis eradication-India, January 2007-May 2009. MMWR Morb Mortal Wkly Rep 2009, 58:719-723. Centers for Disease Control and Prevention.
3. Faden H, Duffy L, Sun M, Shuff C Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. J Infect Dis 1993, 168:452-454.
4. Moriniere BJ, van Loon FP, Rhodes PH, et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 1993, 341:1545-1550.
5. Parent du Châtelet I, Merchant AT, Fisher-Hoch S, et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 2003, 21:1710-1718.
6. Plotkin SA, Vidor E Poliovirus vaccine-inactivated. Vaccines 2008, 605-630. WB Saunders, Philadelphia, PA, USA. 5th edn. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
7. Sutter RW, Patriarca PA Inactivated and live, attenuated poliovirus vaccines:mucosal immunity. Measles and poliomyelitis 1993, 279-293. Springer-Verlag, Austria. E. Kurstak (Ed.).
8. Sutter RW, Suleiman AJ, Malankar PG, et al. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. J Infect Dis 1997, 175(suppl 1):S235-S240.
9. Sutter RW, Suleiman AJ, Malankar P, et al. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 2000, 343:767-773.
10. Swartz TA, Green MS, Handscher R, et al. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel. Vaccine 2008, 26:1083-1090.
11. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. J Infect Dis 1997, 175:S215-S227. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines.
12. Introduction of inactivated poliovirus vaccine into oral poliovirus-vaccine using countries. Wkly Epidemiol Rec 2003, 78:241-250. WHO.
13. Grassly NC, Fraser C, Wenger J, et al. New strategies for the elimination of polio from India. Science 2006, 314:1150-1153.
14. Grassly NC, Wenger J, Durrani S, et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 2007, 369:1356-1362.
15. Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010, 362:2351-2359.
16. Resik S, Tejeda A, Lago PM, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010, 201:1344-1352.
17. Samuel BU, Cherian T, Sridharan G, Mukundan P, John TJ Immune response to intradermally injected inactivated poliovirus vaccine. Lancet 1991, 338:343-344.
18. Report of a WHO Informal consultation on polio neutralizing antibody assays, Nashville, 5-6 December 1991 1991, Expanded Programme on Immunization, World Health Organization, Geneva.
19. R: a language and environment for computing. R Foundation for Statistical Computing R Development Core Team, (accessed Dec 18, 2006). http://www.R-project.org.
20. SAS/STAT user's guide, version 6.4 1989, SAS Institute Inc, SAS Institute, Cary, NC. 4th edn.
21. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age. Methods and development WHO, (accessed Oct 10, 2009). http://www.who.int/childgrowth/standards/Technical_report.pdf.
22. Patriarca PA, Wright PF, John TJ Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991, 13:926-939.
23. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, November 2008. Wkly Epidemiol Rec 2010, 84:17-28. WHO, (in English, French).
24. Böttiger M Polio immunity to killed vaccine: an 18-year follow-up. Vaccine 1990, 8:443-445.
25. Rumke HC, Oostvogel PM, Van Steenis G, Van Loon AM Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Epidemiol Infect 1995, 115:289-298.
26. Kelley PW, Petruccelli BP, Stehr-Green P, Erickson RL, Mason CJ The susceptibility of young adult Americans to vaccine-preventable infections. A national serosurvey of US Army recruits. JAMA 1991, 266:2724-2729.
27. Thompson KM, Tebbens RJ, Pallansch MA, et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health 2008, 98:1322-1330.
28. McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol 1988, 128:615-628.
29. Simasathien S, Migasena S, Beuvery C, et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. Scand J Infect Dis 1994, 26:731-738.
30. Nirmal S, Cherian T, Samuel BU, Rajasingh J, Raghupathy P, John TJ Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 1998, 16:928-931.